Pharmacokinetics of Voxilaprevir in Adults With Normal Renal Function and Severe Renal Impairment

Completed · Phase 1

Conditions studied: HCV Infection

In brief

The primary objective of this study is to evaluate the pharmacokinetics, safety, and tolerability of voxilaprevir (formerly GS-9857) in participants with severe renal impairment and matched healthy control participants.

Key facts

Study ID

NCT02402452

Run by

Gilead Sciences

People needed

20

Starts

2015-05-05

Expected to finish

2015-09-28

Last updated by the study team

2020-03-20

Who can join

Age: 18 and older, up to 79. Sex: any. Healthy volunteers: accepted.

Where it is running

• Orlando Clinical Research Center — Orlando, Florida, United States
• Texas Liver Institute — San Antonio, Texas, United States
• APEX GmbH — München, Germany
• Christchurch Clinical Studies Trust Ltd — Christchurch, New Zealand

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.